Literature DB >> 8607286

DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309.

A J Bett1, V Krougliak, F L Graham.   

Abstract

dl309 is an adenovirus type 5 (Ad5) mutant that has been extensively utilized for construction of Ad5 mutants in early region 1 (E1), in developing vectors for use as viral vaccines, and in development of gene transfer vectors for gene therapy. Ad5 dl309 has been useful for vector construction because of its altered XbaI restriction pattern and lends itself to a variety of strategies for rescuing inserts or mutations into E1. It contains only one XbaI site at 3.7 map units (m.u.) as compared to wt Ad5 which contains 4(3.7, 29.5, 79.5, and 84.8 m.u.). The loss of the sites at 29.5 and 79.5 m.u. is due to deletions of a few bp but the loss of the site at 84.8 m.u. was the result of a deletion from approximately 83 to 85 m.u. and substitution with a fragment of foreign DNA. Because of the widespread use of dl309 and derivatives of this mutant in the construction of Ad5-based vectors and the need to have precise genetic information on the sequences present in vectors to be used as vaccines and in gene therapy, we have sequenced the alterations in dl309 which affect the XbaI sites at 79.5 and 84.8 m.u. and have determined which E3 proteins are expressed by this virus. The deletion that removes the XbaI site at 84.8 m.u. extends from Ad5 bp 30005-30750 and is substituted with 642-bp of heterologous DNA that shows homology to salmon DNA. This alteration deletes all or part of the coding sequences for the E3 14.7K, 14.5K and 10.4K proteins and these proteins are not detected in dl309 infected cells. The loss of the XbaI site at 79.5 m.u. is the result of a 6-bp deletion which removes two internal amino acids (18 and 19) from the E3 6.7K protein. The E3 6.7K protein and other E3 proteins whose coding sequences are unaffected by the alterations in dl309 (gp19K, 12.5K and 11.6K) were expressed in dl309 infected cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8607286

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  25 in total

1.  Readthrough activation of early adenovirus E1b gene transcription.

Authors:  L F Maxfield; D J Spector
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2.

Authors:  Drew L Lichtenstein; Konstantin Doronin; Karoly Toth; Mohan Kuppuswamy; William S M Wold; Ann E Tollefson
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  Thermostability/infectivity defect caused by deletion of the core protein V gene in human adenovirus type 5 is rescued by thermo-selectable mutations in the core protein X precursor.

Authors:  Hideyo Ugai; Anton V Borovjagin; Long P Le; Minghui Wang; David T Curiel
Journal:  J Mol Biol       Date:  2006-12-06       Impact factor: 5.469

4.  Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B.

Authors:  Brian P McSharry; Hans-Gerhard Burgert; Douglas P Owen; Richard J Stanton; Virginie Prod'homme; Martina Sester; Katja Koebernick; Veronika Groh; Thomas Spies; Steven Cox; Ann-Margaret Little; Eddie C Y Wang; Peter Tomasec; Gavin W G Wilkinson
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

5.  A novel hybrid adenoretroviral vector with more extensive E3 deletion extends transgene expression in submandibular glands.

Authors:  Changyu Zheng; Ana P Cotrim; Nikolay Nikolov; Fumi Mineshiba; William Swaim; Bruce J Baum
Journal:  Hum Gene Ther Methods       Date:  2012-07-20       Impact factor: 2.396

6.  Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development.

Authors:  Gabriel Glockzin; Klaus Mantwill; Karsten Jurchott; Alexandra Bernshausen; Axel Ladhoff; Hans-Dieter Royer; Bernd Gansbacher; Per Sonne Holm
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.

Authors:  Zebin Hu; Helen Gerseny; Zhenwei Zhang; Yun-Ju Chen; Arthur Berg; Zhiling Zhang; Stuart Stock; Prem Seth
Journal:  Mol Ther       Date:  2011-06-28       Impact factor: 11.454

8.  The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells.

Authors:  A E Tollefson; A Scaria; T W Hermiston; J S Ryerse; L J Wold; W S Wold
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus.

Authors:  J M Torres; C Alonso; A Ortega; S Mittal; F Graham; L Enjuanes
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models.

Authors:  Roma Yumul; Maximilian Richter; Zhuo-Zhuang Lu; Kamola Saydaminova; Hongjie Wang; Chung-Huei Katherine Wang; Darrick Carter; André Lieber
Journal:  Hum Gene Ther       Date:  2016-04       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.